Spots Global Cancer Trial Database for Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
Official Title: Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
Study ID: NCT04192682
Conditions
Interventions
Study Description
Brief Summary: Immunotherapy combined with anti-angiogenic therapy can achieve better results in patients with second-line and above small cell lung cancer
Detailed Description: Through this study, it was found that Anlotinib combined with Sintilimab has a better survival benefit. At the same time, genetic analysis and immunohistochemical methods have been used to predict the predictive value of targeted therapy combined with Sintilimab.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Changzhou Cancer Hospital of Soochow University, Changzhou, Jiangsu, China
Contact Details
Name: Tong Zhou
Affiliation: Changzhou Cancer Hospital of Soochow University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
